News

Basilea Pharmaceutica’s (Basilea) anti-infective compounds ceftobiprole, isavuconazole and the novel antibiotic BAL30072’s data were presented at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San

The FDA has approved Sanofi Pasteur’s supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine. Monovalent Vaccine is an inactivated influenza virus

The FDA has granted Orphan Drug Designation to Advanced Life Sciences’ Restanza (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Advanced

Poniard Pharmaceuticals (Poniard) has announced that 320 evaluable events (patient deaths) have occurred in its pivotal phase 3 SPEAR trial. The trial is being conducted in accordance with

Jim Manzi, chairman of the board, said, “Marc’s strong leadership at Thermo Fisher over the past eight years and his achievements both here and in other companies make

The FDA has approved the design of a single, pivotal, phase III clinical trial evaluating BioVex’s lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous

Cell Therapeutics (CTI) has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for

Amgen has announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court’s decision that Roche’s peg-EPO product, Mircera, infringes four Amgen patents (‘868,

Lexicon Pharmaceuticals (Lexicon) has initiated a phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug